JNCI-J NATL CANCER I 润色咨询

JNCI-Journal of the National Cancer Institute

出版年份:暂无数据 年文章数:3695 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:1.6% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2018-12-14 jfazj

    Submission Technical Check Started状态持续了快半个月了,是不是放假了?

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-09-04 ms9508293866653270 来自陕西省

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享:很好的期刊,只是这些年有点落寞了,不好中

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-07-23 ms6000001984003159 来自广东省

    偏重的研究方向:肿瘤
    经验分享:投稿后,under consideration4周了

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-07-30 ms2000000185262432 来自广西

    投稿命中率:25.0
    偏重的研究方向:甲状腺肿瘤
    经验分享:Submission Technical Check Started:一周
    Under consideration:一周
    rejected

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2020-05-25 ms6000001848255584

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:肿瘤免疫
    经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。

    4

    展开4条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2022-11-05 slientwo

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤;Cancer
    经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2018-03-17 Dr. H

    博士.结果怎么样?jfazj 2017-10-17 发表::
    研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!
    jfazj 2017-10-17 11:09:00 发表:
    mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!

    jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2021-12-14 OceanSL

    很快变成review complete 是不是秒拒

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2021-12-29 ms6000000264964247

    常见的SCI文章类型有哪些?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了,是不是放假了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:很好的期刊,只是这些年有点落寞了,不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向:肿瘤<br>经验分享:投稿后,under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0<br>偏重的研究方向:甲状腺肿瘤<br>经验分享:Submission Technical Check Started:一周<br>Under consideration:一周<br>rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:1月23日过年之前投一篇article,3月3日审稿回来大修。三个审稿人一个没意见,另外俩一共提了9个意见,都还比较到要害,可见审稿人水平很高。一个月时间修改后发回,5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;Cancer<br>经验分享:杂志主要接收临床相关的文章,观点新颖,提出新的肿瘤治疗方案,并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章,还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?<span class="quote">jfazj 2017-10-17 发表::<br>研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span><span class="quote">jfazj 2017-10-17 11:09:00 发表:<br>mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!</span>, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093754, encodeId=5bc41093e54fa, content=我们做研究时最常见或撰写的SCI文章类型是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2021-12-27 MS68862005

    我们做研究时最常见或撰写的SCI文章类型是什么?

    1

    展开1条回复
共61条页码: 1/7页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分